Zydus receives EIR for the transdermal manufacturing facility
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
The product is expected to be launched in Q3FY25
The inspection conducted by EDQM at its Visakhapatnam facility
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
He holds a Master’s in Management from the National University of Singapore
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Developed in consultation with clinicians and patients for an enhanced user experience
Subscribe To Our Newsletter & Stay Updated